October 10, 2025

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a Potential 98% Upside

Organogenesis Holdings Inc. (NASDAQ: ORGO), a key player in the regenerative medicine sector, offers a compelling investment opportunity with a potential upside of 98.02%. This potential is driven by an..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: A Biotech Prospect with 13% Upside Potential

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is capturing the attention of investors with its promising outlook in the biotech sector. As a clinical-stage pharmaceutical company, Amylyx is focused on developing treatment..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a Complex Landscape with Strategic Partnerships

Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent player in the healthcare sector, specializes in molecular diagnostic testing and precision medicine. With a market capitalization of $720.17 million, this Salt Lake..

Treace Medical Concepts, Inc. (TMCI): Analyst Ratings and Target Price Suggest a 42% Upside Potential

Treace Medical Concepts, Inc. (NASDAQ: TMCI) is a noteworthy player in the healthcare sector, specifically within the medical devices industry. As a U.S.-based company with a market capitalization of approximately..

Autolus Therapeutics plc (AUTL) Stock Analysis: A Deep Dive into Its 446.72% Potential Upside

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical innovator from the United Kingdom, has captured the attention of investors with its promising pipeline of T cell therapies targeting cancer and..

OrthoPediatrics Corp. (KIDS) Investor Outlook: Analyzing a Potential 79% Upside in the Pediatric Orthopedic Market

OrthoPediatrics Corp. (NASDAQ: KIDS) has positioned itself as a pivotal player in the healthcare sector, particularly within the niche market of pediatric orthopedic medical devices. Headquartered in Warsaw, Indiana, this..

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Unpacking a 271.95% Potential Upside

Cullinan Therapeutics, Inc. (NASDAQ: CGEM), a clinical-stage biopharmaceutical company, has caught the attention of investors with its impressive potential upside of 271.95%. This Massachusetts-based firm, specializing in developing therapies for..

Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Exploring a Potential 165% Upside

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a promising player in the biotech sector, is attracting significant attention from investors with its remarkable potential for growth. With a current market cap of..

Claritev Corporation (CTEV) Stock Analysis: Unpacking the 20.86% Potential Upside

Claritev Corporation (NASDAQ: CTEV), a prominent player in the healthcare information services sector, has been capturing investor attention with its innovative solutions aimed at reducing healthcare costs and improving operational..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Biotech with Over 112% Potential Upside

Niagen Bioscience, Inc. (NAGE), a prominent player in the biotechnology industry, is attracting the attention of investors with its impressive potential upside of 112.17%. Specializing in developing healthy aging products,..

Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator with a 50.60% Upside Potential

Celcuity Inc. (CELC), a Minneapolis-based clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative approach to treating solid tumors. Founded in 2011, Celcuity has carved a..

RxSight, Inc. (RXST) Investor Outlook: Navigating the Market with a 9.60% Potential Upside

RxSight, Inc. (NASDAQ: RXST) offers a unique proposition within the healthcare sector, specifically in the medical devices industry. Known for its innovative approach to cataract surgery, RxSight has carved a..

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Exploring a Potential 146.27% Upside in the Biotechnology Sector

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is generating significant buzz in the biotechnology sector, thanks to a promising pipeline of treatments aimed at serious retinal diseases. With an impressive average target..

Cross Country Healthcare, Inc. (CCRN)

⚠️ No article content returned.

..

Valneva SE (VALN) Stock Analysis: A Biotech with a 20% Upside Potential

Valneva SE (NASDAQ: VALN), a French biotechnology company, is capturing the attention of individual investors with its promising pipeline of vaccines targeting infectious diseases. Specializing in prophylactic vaccines, Valneva is..

Semler Scientific, Inc. (SMLR) Investor Outlook: A Healthcare Innovator with 166% Potential Upside

Semler Scientific, Inc. (NASDAQ: SMLR) is making waves in the healthcare sector, driven by its innovative medical devices aimed at enhancing clinical efficiency. Headquartered in Santa Clara, California, this company..

MeiraGTx Holdings plc (MGTX): Explosive Growth Potential with 212% Upside

MeiraGTx Holdings plc (NASDAQ: MGTX) is capturing the attention of investors with its compelling storyline in the biotechnology sector. With an impressive market cap of $704.72 million, this clinical-stage genetics..

AxoGen, Inc. (AXGN) Stock Report: Analyzing a 50% Upside Potential in the Medical Devices Sector

Investors looking for promising opportunities in the healthcare sector may find AxoGen, Inc. (NASDAQ: AXGN) worthy of consideration. Specializing in the niche market of peripheral nerve regeneration and repair, AxoGen..

Opthea Limited (OPT) Stock Analysis: Navigating the -70.67% Potential Downside

Opthea Limited (ASX: OPT) stands on the cusp of significant developments in the biotechnology sector with its promising clinical-stage biopharmaceutical pipeline. Based in Melbourne, Australia, Opthea is a key player..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring a 109.60% Potential Upside in the Biotech Sector

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) presents a compelling case for investors keen on venturing into the biotechnology sector, an industry known for its high risk and high reward dynamics. With..

Search

Funds

October 10, 2025

Search

Funds

October 10, 2025

FTSE 100

Funds